Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant

• Status: Completed
• Trial end date: 2004-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to prevent reactivation of herpes zoster during the first year after transplant.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fred Hutchinson Cancer Research Center
• Collaborators: Burroughs Wellcome; National Institutes of Health (NIH)
• Treatments: Acyclovir

Criteria

Inclusion Criteria:

• 10 years or older

• Both sex (male or female)

• Allogeneic transplant patient for hematologic malignancy or aplastic anemia

Exclusion Criteria:

• Previous intolerance to acyclovir

• Patients who are unavailable for follow-up

• Patients in whom drug compliance may be a problem

• Evidence of active VZV infection

• VZV infection in the initial 1 month after transplant

• Pregnant women, lactating women, or those not using adequate contraception

• Creatinine > 3.0 mg/dl.